Biotin-Conjugated Multilayer Poly [D,L-lactide-co-glycolide]-Lecithin-Polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin

Dai, Yu; Xing, Haizhou; Song, Fuling; Yang, Yue; Qiu, Zhixia; Lu, Xiaoyu; Liu, Qi; Ren, Shuangxia; Chen, Xijing; Li, Ning

doi:10.1016/j.xphs.2016.03.038

Cited by 28 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The liposomal shells are surrounded by a polyethylene glycol (PEG) layer which provides a hydrophilic protective barrier between the liposome and the surroundings to achieve sustained drug release 30. In addition, liposomes have a great affinity for retina, which can provide high local availability 31.…”

Section: Discussionmentioning

confidence: 99%

Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes

Zhang

Jiao

et al. 2017

Br J Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes

Zhang

Jiao

et al. 2017

Br J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…The biotin-mediated DDS for targeted tumour delivery of doxorubicin was obtained by a modified nanoprecipitation method combined with self-assembly [120]. The structure of the multilayer Dox-PLGA-lecithin-PEG-biotin nanoparticles with an average diameter of 110 nm is presented in Figure 5.…”

Section: Drug-delivery Applicationmentioning

confidence: 99%

“…A schematic presentation (A) and TEM image at a scale = 100 nm (B) of DOX-PLGA-lecithin-PEG-biotin nanoparticles (B). With permission from Dai et al[120].…”

mentioning

confidence: 99%

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

et al. 2021

View full text Add to dashboard Cite

Cancer is one of the major causes of death worldwide and its treatment remains very challenging. The effectiveness of cancer therapy significantly depends upon tumour-specific delivery of the drug. Nanoparticle drug delivery systems have been developed to avoid the side effects of the conventional chemotherapy. However, according to the most recent recommendations, future nanomedicine should be focused mainly on active targeting of nanocarriers based on ligand-receptor recognition, which may show better efficacy than passive targeting in human cancer therapy. Nevertheless, the efficacy of single-ligand nanomedicines is still limited due to the complexity of the tumour microenvironment. Thus, the NPs are improved toward an additional functionality, e.g., pH-sensitivity (advanced single-targeted NPs). Moreover, dual-targeted nanoparticles which contain two different types of targeting agents on the same drug delivery system are developed. The advanced single-targeted NPs and dual-targeted nanocarriers present superior properties related to cell selectivity, cellular uptake and cytotoxicity toward cancer cells than conventional drug, non-targeted systems and single-targeted systems without additional functionality. Folic acid and biotin are used as targeting ligands for cancer chemotherapy, since they are available, inexpensive, nontoxic, nonimmunogenic and easy to modify. These ligands are used in both, single- and dual-targeted systems although the latter are still a novel approach. This review presents the recent achievements in the development of single- or dual-targeted nanoparticles for anticancer drug delivery.

show abstract

“…Moreover, the use of polyethylene glycol (PEG) imparts stealth properties on nanoparticles (19), reducing the tendency to be eliminated by the reticuloendothelial system (RES), improving bioavailability and half-life of drug (20). The hydrophilic properties of PEG could prevent interaction with other nanoparticles via sterical hindrance, improving the stability of nanoparticles (21). PEG is also claimed to enhance mucoadhesive of nanoparticles (22).…”

Section: Introductionmentioning

confidence: 99%

PEGylated Lipid Polymeric Nanoparticle–Encapsulated Acyclovir for In Vitro Controlled Release and Ex Vivo Gut Sac Permeation

et al. 2020

View full text Add to dashboard Cite

Currently, pharmaceutical research is directed wide range for developing new drugs for oral administration to target disease. Acyclovir formulation is having common issues of short half-life and poor permeability, causing messy treatment which results in patient incompliance. The present study formulates a lipid polymeric hybrid nanoparticles for antiviral acyclovir (ACV) agent with Phospholipon® 90G (lecithin), chitosan, and polyethylene glycol (PEG) to improve controlled release of the drugs. The study focused on the encapsulation of the ACV in lipid polymeric particle and their sustained delivery. The formulation developed for the self-assembly of chitosan and lecithin to form a shell encapsulating acyclovir, followed by PEGylation. Optimisation was performed via Box-Behnken Design (BBD), forming nanoparticles with size of 187.7 ± 3.75 nm, 83.81 ± 1.93% drug-entrapped efficiency (EE), and + 37.7 ± 1.16 mV zeta potential. Scanning electron microscopy and transmission electron microscopy images displayed spherical nanoparticles formation. Encapsulation of ACV and complexity with other physical parameters are confirmed through analysis using Fourier transform infrared spectroscopy, differential scanning calorimetry, and X-ray diffraction. Nanoparticle produced was capable of achieving 24-h sustained release in vitro on gastric and intestinal environments. Ex vivo study proved the improvement of acyclovir's apparent permeability from 2 × 10 −6 to 6.46 × 10 −6 cm s −1. Acyclovir new formulation was achieved to be stable up to 60 days for controlled release of the drugs.

show abstract

Biotin-Conjugated Multilayer Poly [D,L-lactide-co-glycolide]-Lecithin-Polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin

Cited by 28 publications

References 29 publications

Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes

Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

PEGylated Lipid Polymeric Nanoparticle–Encapsulated Acyclovir for In Vitro Controlled Release and Ex Vivo Gut Sac Permeation

Contact Info

Product

Resources

About